Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 8 of 8 results for isotretinoin

  1. Acne vulgaris: management (NG198)

    This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

  2. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  3. Oral isotretinoin treatment: What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?

    NG198/1 Question Oral isotretinoin treatment: What is the efficacy of reduced dose oral isotretinoin in the management of...

  4. What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?

    NG198/1 Question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Any explanatory notes(if...

  5. LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

    NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands

  6. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

  7. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  8. Research recommendations

    NG198/1 | Oral isotretinoin treatment: What is the efficacy of reduced dose oral isotretinoin in the management of acne...